Rational Design of Loss-of-Function Phospholamban Mutants for Gene Therapy
Rational Design of Loss-of-Function Phospholamban Mutants for Gene Therapy
批准号:
7769552
负责人:
Kim N Ha
金额:
$3.04万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-02-16 至 2012-02-15
关键词:
AffectAffinityAnimalsAttenuatedBindingBiochemicalBiologicalBiological AssayCa(2+)-Transporting ATPaseCandidate Disease GeneCardiacCardiac MyocytesCardiomyopathiesCollaborationsCommunicationCoupledDataDilated CardiomyopathyDiseaseDouble EffectEngineeringEnzymesEscherichia coliFunctional disorderGeneticGoalsHeart DiseasesHeart failureHumanLearningMembraneMethodsMicellesModelingMolecularMusMuscle relaxation phaseMutagenesisMutationMyocardiumNMR SpectroscopyOutcomePaperPathway interactionsPhosphorylationPhysiologyProtein BiochemistryPublicationsRecombinant adeno-associated virus (rAAV)RegulationReticulumRoleSite-Directed MutagenesisSolutionsStructureTechniquesTestingTherapeuticTranslatingTransmembrane DomainUniversitiesWorkanalogbasedesigndodecylphosphocholinegene therapyimprovedinhibitor/antagonistinnovationinsightinterestintermolecular interactionloss of functionmutantnovel therapeuticsphospholambanpublic health relevancesuccess
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The overall goal of this proposal is to rationally design "loss of function" phospholamban (PLN) mutant candidates for the purpose of ameliorating the onset of cardiomyopathy by recombinant adeno-associated virus (rAAV) gene therapy. PLN is the endogenous inhibitor of the sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA), the integral membrane enzyme responsible for 70% of the Ca2+ shuttling into the SR, inducing cardiac muscle relaxation in humans. Dysfunctions in SERCA:PLN interactions have been implicated as having a role in cardiac disease. The pathway to innovating genetic treatments for dysfunctions of SERCA and PLN interactions has recently become a new interest in the field due to the success of S16E, a pseudo-phosphorylated form of PLN which successfully reduced the progression of the cardiac failure in murine models and large animals. It has been found that the structural dynamics of PLN can be tuned to result in a directed functional effect on SERCA , and this study aims to innovate other candidates like S16E for use in gene therapy in treatment of heart failure. This proposal will concentrate on several key components of the domain-oriented rational design of PLN mutant species, and focus on these specific aims: AIM 1: Define the role of domain communication in PLN's ability to inhibit SERCA. AIM 2: Structural-dynamic-functional characterization of dual pseudo-phosphorylated PLN (S16E/T17E). AIM 3: Elucidate the significance of "superinhibitors" of PLN. New PLN mutant species will be developed using site-directed mutagenesis and expressed in Escherichia coli and purified using established methods. To characterize these new PLN mutants in their unphosphorylated and phosphorylated states, the structural-dynamics will be studied using solution-state nuclear magnetic resonance (NMR) spectroscopy in dodecylphosphocholine (DPC) micelles. The resulting perturbations in the structural-dynamics will be then correlated to functional effects observed in coupled enzyme assays in the presence of SERCA. From the insight of this work, the aim of this proposal is to rationally design new PLN mutant candidates for gene therapy and establish new principles for the successful design of therapeutic PLN analogs. PUBLIC HEALTH RELEVANCE: By controlling the function of an enyzme by acting on the structural dynamic of its' subunits, the results of this study aim to move from understanding the interplay of structural dynamics of controlling physiology at a molecular level.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Rational Design of Loss-of-Function Phospholamban Mutants for Gene Therapy
-
批准号:8035358
-
项目类别:
-
资助金额:$2.73万
-
财政年份:2009
-
负责人:Kim N Ha
-
依托单位:
Rational Design of Loss-of-Function Phospholamban Mutants for Gene Therapy
-
批准号:7616331
-
项目类别:
-
资助金额:$3.25万
-
财政年份:2009
-
负责人:Kim N Ha
-
依托单位:
海外基金